flosequinoxan has been researched along with milrinone in 3 studies
*Milrinone: A positive inotropic cardiotonic agent with vasodilator properties. It inhibits cAMP phosphodiesterase type 3 activity in myocardium and vascular smooth muscle. Milrinone is a derivative of amrinone and has 20-30 times the inotropic potency of amrinone. [MeSH]
*Milrinone: A positive inotropic cardiotonic agent with vasodilator properties. It inhibits cAMP phosphodiesterase type 3 activity in myocardium and vascular smooth muscle. Milrinone is a derivative of amrinone and has 20-30 times the inotropic potency of amrinone. [MeSH]
| Studies (flosequinoxan) | Trials (flosequinoxan) | Recent Studies (post-2010) (flosequinoxan) | Studies (milrinone) | Trials (milrinone) | Recent Studies (post-2010) (milrinone) |
|---|---|---|---|---|---|
| 11 | 2 | 0 | 1,605 | 235 | 452 |
| Protein | Taxonomy | flosequinoxan (IC50) | milrinone (IC50) |
|---|---|---|---|
| Phosphodiesterase | Bos taurus (cattle) | 1 | |
| cGMP-dependent 3',5'-cyclic phosphodiesterase | Homo sapiens (human) | 0.3 | |
| High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8A | Homo sapiens (human) | 0.3 | |
| cGMP-specific 3',5'-cyclic phosphodiesterase | Homo sapiens (human) | 0.52 | |
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | 4.7 | |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Homo sapiens (human) | 6 | |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4B | Homo sapiens (human) | 6 | |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4C | Homo sapiens (human) | 6 | |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4D | Homo sapiens (human) | 3.15 | |
| cGMP-inhibited 3',5'-cyclic phosphodiesterase B | Homo sapiens (human) | 1.8674 | |
| cGMP-inhibited 3',5'-cyclic phosphodiesterase A | Homo sapiens (human) | 1.8177 | |
| cGMP-specific 3',5'-cyclic phosphodiesterase | Bos taurus (cattle) | 5 | |
| Phosphodiesterase | Sus scrofa (pig) | 0.843 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hague, NL; Hunneyball, IM; Loh, E; Morgan, JP; Perreault, CL; Sim, MF | 1 |
| Britton, LW; Ferraris, VA; Kiser, LM; Sim, MF; Wallace, AM; Weishaar, RE | 1 |
| Britton, LW; Ferraris, VA; Kirker, ML; Sim, MF; Wallace, AM; Weishaar, RE | 1 |
3 other study(ies) available for flosequinoxan and milrinone
| Article | Year |
|---|---|
Differential inotropic effects of flosequinan in ventricular muscle from normal ferrets versus patients with end-stage heart failure.
Topics: Animals; Calcium; Colforsin; Dose-Response Relationship, Drug; Ferrets; Heart Failure; Heart Ventricles; Humans; In Vitro Techniques; Male; Milrinone; Myocardial Contraction; Pyridones; Quinolines; Quinolones; Stimulation, Chemical; Vasodilator Agents | 1992 |
Assessment of flosequinan's direct effect on human arterial, venous, and cardiac muscle: comparison with other classes of agents used to treat heart failure.
Topics: Captopril; Diltiazem; Heart Failure; Humans; In Vitro Techniques; Milrinone; Muscle Contraction; Muscle, Smooth, Vascular; Myocardial Contraction; Ouabain; Pyridones; Quinolines; Quinolones; Vasodilator Agents | 1994 |
Relationship between inotropic activity and phosphodiesterase inhibition for flosequinan and milrinone.
Topics: Humans; In Vitro Techniques; Milrinone; Myocardial Contraction; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Pyridones; Quinolines; Quinolones; Vasodilation | 1993 |